Gwendolyn Wu
Senior reporterGwendolyn is a senior reporter at BioPharma Dive covering biotech startups, venture capital and the ecosystem that supports them. Previously, she authored Bay Briefing, the San Francisco Chronicle’s flagship weekday newsletter, and covered COVID-19 and the business of healthcare for the Houston Chronicle. Outside of the newsroom, Gwendolyn teaches at the California Scholastic Press Association summer workshop for high school journalists, and has led student and early career programs for the Asian American Journalists Association. She has degrees in history and sociology from the University of California at Santa Barbara.
370 articles by Gwendolyn Wu
-
Vertex’s CRISPR therapy rebounds in latest earnings
Feb. 13, 2026 -
FDA rejects Regenxbio treatment in another blow to gene therapy
Feb. 10, 2026 -
Agomab, SpyGlass bank a combined $350M in biotech IPOs
Feb. 5, 2026 -
Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings
Feb. 4, 2026 -
Tenpoint wins FDA nod for combination presbyopia eye drop
Jan. 29, 2026 -
An immune drug developer raises $50M to finance its eczema drug testing
Jan. 27, 2026 -
Investors load Corxel with $287M for a ‘differentiated’ obesity pill
Jan. 22, 2026 -
Kailera’s Ron Renaud on how a China-linked startup can compete in obesity
Jan. 20, 2026 -
Aktis raises $318M in 2026’s first biotech IPO
Jan. 8, 2026 -
Diagonal banks another $125M for ‘clustering’ antibody drugs
Jan. 8, 2026 -
EpiBiologics raises $107M for its protein-degrading cancer drug
Jan. 8, 2026 -
Amgen buys protein-degrading startup Dark Blue for up to $840M
Jan. 6, 2026 -
Orum, a biotech marrying ADCs with protein degraders, captures $100M in funding
Dec. 18, 2025 -
Addition emerges with $100M to make gene therapies for chronic and rare diseases
Dec. 17, 2025 -
‘Zombie’ biotech buyer Xoma to acquire Generation Bio
Dec. 16, 2025 -
Biotech venture firm Apple Tree goes bankrupt amid dispute with billionaire backer
Dec. 11, 2025 -
Prolynx banks $70M for longer-lasting obesity drugs
Dec. 11, 2025 -
A Roivant spinout bets on AI-designed drugs for immune conditions
Dec. 10, 2025 -
Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay
Dec. 8, 2025 -
With $130M, Protego pushes forward a new type of amyloidosis drug
Dec. 1, 2025 -
Aspen raises $115M for a Parkinson’s stem cell treatment
Nov. 20, 2025 -
Zymeworks to change course, pursue ‘royalty-driven’ biotech model
Nov. 18, 2025 -
A ‘DNA damage repair’ drugmaker raises $115M for cancer treatments
Nov. 17, 2025 -
Sofinnova Partners raises another $750M to back biotech, medtech startups
Nov. 16, 2025 -
Medicxi closes sixth fund to back ‘asset-centric’ startups
Nov. 14, 2025
